Drugging IGF-1R in cancer: New insights and emerging opportunities

Weinstein, 2013, The cancer Genome atlas pan-cancer analysis project, Nat Genet, 45, 1113, 10.1038/ng.2764 Denduluri, 2015, Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance, Genes Dis, 2, 13, 10.1016/j.gendis.2014.10.004 Lee, 2016, Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells, Mol Carcinog, 55, 991, 10.1002/mc.22342 Browne, 2011, Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells, Ann Oncol, 22, 68, 10.1093/annonc/mdq349 Brahmkhatri, 2015, Insulin-like growth factor system in cancer: novel targeted therapies, BioMed Res Int, 2015, 538019, 10.1155/2015/538019 Evdokimova, 2012, IGFBP7 binds to the IGF-1 receptor and blocks its activation by insulin-like growth factors, Sci Signal, 5, ra92, 10.1126/scisignal.2003184 Bach, 2018, IGF-binding proteins, J Mol Endocrinol, 61, T11, 10.1530/JME-17-0254 Chitnis, 2008, The type 1 insulin-like growth factor receptor pathway, Clin Cancer Res, 14, 6364, 10.1158/1078-0432.CCR-07-4879 Baxter, 2014, IGF binding proteins in cancer: mechanistic and clinical insights, Nat Rev Cancer, 14, 329, 10.1038/nrc3720 Pollak, 2012, The insulin and insulin-like growth factor receptor family in neoplasia: an update, Nat Rev Cancer, 12, 159, 10.1038/nrc3215 Tognon, 2012, Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy, Expert Opin Ther Targets, 16, 33, 10.1517/14728222.2011.638626 Adams, 2000, Structure and function of the type 1 insulin-like growth factor receptor, Cell Mol Life Sci, 57, 1050, 10.1007/PL00000744 Arcaro, 2013, Targeting the insulin-like growth factor-1 receptor in human cancer, Front Pharmacol, 4, 30, 10.3389/fphar.2013.00030 Mancarella, 2021, Novel regulators of the IGF system in cancer, Biomolecules, 11, 273, 10.3390/biom11020273 Pandini, 2002, Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved, J Biol Chem, 277, 39684, 10.1074/jbc.M202766200 Rozengurt, 2010, Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer, Clin Cancer Res, 16, 2505, 10.1158/1078-0432.CCR-09-2229 Sanabria-Figueroa, 2015, Insulin-like growth factor-1 receptor signaling increases the invasive potential of human epidermal growth factor receptor 2-overexpressing breast cancer cells via Src-focal adhesion kinase and forkhead box protein M1, Mol Pharmacol, 87, 150, 10.1124/mol.114.095380 Cevenini, 2018, Molecular signatures of the insulin-like growth factor 1-mediated epithelial-mesenchymal transition in breast, lung and gastric cancers, Int J Mol Sci, 19, E2411, 10.3390/ijms19082411 Aleksic, 2017, IGF-1R associates with adverse outcomes after radical radiotherapy for prostate cancer, Br J Cancer, 117, 1600, 10.1038/bjc.2017.337 Dale, 2015, IGF-1R expression is associated with HPV-negative status and adverse survival in head and neck squamous cell cancer, Carcinogenesis, 36, 648, 10.1093/carcin/bgv053 Farabaugh, 2015, Role of IGF1R in breast cancer subtypes, stemness, and lineage differentiation, Front Endocrinol, 6, 59, 10.3389/fendo.2015.00059 Solomon-Zemler, 2017, Nuclear insulin-like growth factor-1 receptor (IGF1R) displays proliferative and regulatory activities in non-malignant cells, PLoS One, 12, e0185164, 10.1371/journal.pone.0185164 Alkhayyal, 2020, Correlation of insulin-like growth factor 1 receptor expression with different molecular subtypes of breast cancer in the UAE, Anticancer Res, 40, 1555, 10.21873/anticanres.14102 Ekyalongo, 2017, Revisiting the IGF-1R as a breast cancer target, NPJ Precis Oncol, 1, 14, 10.1038/s41698-017-0017-y Nahta, 2005, Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells, Cancer Res, 65, 11118, 10.1158/0008-5472.CAN-04-3841 Kang, 2014, Association of polymorphisms and haplotypes in the insulin-like growth factor 1 receptor (IGF1R) gene with the risk of breast cancer in Korean women, PLoS One, 9, e84532, 10.1371/journal.pone.0084532 Stanilov, 2014, Association of insulin-like growth factor-I receptor polymorphism with colorectal cancer development, Mol Biol Rep, 41, 8099, 10.1007/s11033-014-3708-2 Dong, 2010, Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer, Gastroenterology, 139, 464, 10.1053/j.gastro.2010.04.042 Yuan, 2020, A possible link of genetic variations in ER/IGF1R pathway and risk of melanoma, Int J Mol Sci, 21, E1776, 10.3390/ijms21051776 Powell, 2019, Pregnancy hypertension and a commonly inherited IGF1R variant (rs2016347) reduce breast cancer risk by enhancing mammary gland involution, JAMA Oncol, 2019, 6018432 Sarfstein, 2012, Insulin-like growth factor-I receptor (IGF-IR) translocates to nucleus and autoregulates IGF-IR gene expression in breast cancer cells, J Biol Chem, 287, 2766, 10.1074/jbc.M111.281782 Yuen, 2007, The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma, Oncogene, 26, 6499, 10.1038/sj.onc.1210474 Werner, 2012, Tumor suppressors govern insulin-like growth factor signaling pathways: implications in metabolism and cancer, Oncogene, 31, 2703, 10.1038/onc.2011.447 Schayek, 2010, Transcription factor E2F1 is a potent transactivator of the insulin-like growth factor-I receptor (IGF-IR) gene, Growth Hormone IGF Res, 20, 68, 10.1016/j.ghir.2009.08.001 Sun, 2018, Up-regulation of INSR/IGF1R by C-myc promotes TSCC tumorigenesis and metastasis through the NF-κB pathway, Biochim Biophys Acta BBA Mol Basis Dis, 1864, 1873, 10.1016/j.bbadis.2018.03.004 Werner, 2018, Oncogenic fusion proteins adopt the insulin-like growth factor signaling pathway, Mol Cancer, 17, 28, 10.1186/s12943-018-0807-z Idelman, 2003, WT1-p53 interactions in insulin-like growth factor-I receptor gene regulation, J Biol Chem, 278, 3474, 10.1074/jbc.M211606200 Abramovitch, 2003, BRCA1-Sp1 interactions in transcriptional regulation of the IGF-IR gene, FEBS Lett, 541, 149, 10.1016/S0014-5793(03)00315-6 Riedemann, 2007, The EGF receptor interacts with the type 1 IGF receptor and regulates its stability, Biochem Biophys Res Commun, 355, 707, 10.1016/j.bbrc.2007.02.012 Lukanova, 2002, Circulating levels of insulin-like growth factor-I and risk of ovarian cancer, Int J Cancer, 101, 549, 10.1002/ijc.10613 Roddam, 2008, Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies, Ann Intern Med, 149, 461, 10.7326/0003-4819-149-7-200810070-00006 Qian, 2020, Circulating insulin-like growth factor-1 and risk of total and 19 site-specific cancers: cohort study analyses from the UK biobank, Cancer Epidemiol Biomarkers Prev, 29, 2332, 10.1158/1055-9965.EPI-20-0743 Unger, 2017, Stromal-derived IGF2 promotes colon cancer progression via paracrine and autocrine mechanisms, Oncogene, 36, 5341, 10.1038/onc.2017.116 Bianconi, 2016, Integrins in the spotlight of cancer, Int J Mol Sci, 17, E2037, 10.3390/ijms17122037 Takada, 2017, Crosstalk between insulin-like growth factor (IGF) receptor and integrins through direct integrin binding to IGF1, Cytokine Growth Factor Rev, 34, 67, 10.1016/j.cytogfr.2017.01.003 Fujita, 2012, Cross-talk between integrin alpha6beta4 and insulin-like growth factor-1 receptor (IGF1R) through direct alpha6beta4 binding to IGF1 and subsequent alpha6beta4-IGF1-IGF1R ternary complex formation in anchorage-independent conditions, J Biol Chem, 287, 12491, 10.1074/jbc.M111.304170 Cedano Prieto, 2017, Direct integrin binding to insulin-like growth factor-2 through the C-domain is required for insulin-like growth factor receptor type 1 (IGF1R) signaling, PLoS One, 12, e0184285, 10.1371/journal.pone.0184285 Lin, 2012, An activity-based probe reveals dynamic protein-protein interactions mediating IGF-1R transactivation by the GABA(B) receptor, Biochem J, 443, 627, 10.1042/BJ20120188 Arang, 2020, G Protein-Coupled receptors and heterotrimeric G proteins as cancer drivers, FEBS Lett, 594, 4201, 10.1002/1873-3468.14017 Hallak, 2000, Association of heterotrimeric G(i) with the insulin-like growth factor-I receptor. Release of G(betagamma) subunits upon receptor activation, J Biol Chem, 275, 2255, 10.1074/jbc.275.4.2255 Dalle, 2001, Insulin and insulin-like growth factor I receptors utilize different G protein signaling components, J Biol Chem, 276, 15688, 10.1074/jbc.M010884200 Luttrell, 1995, G beta gamma subunits mediate mitogen-activated protein kinase activation by the tyrosine kinase insulin-like growth factor 1 receptor, J Biol Chem, 270, 16495, 10.1074/jbc.270.28.16495 Schillaci, 2006, Immunization with murine breast cancer cells treated with antisense oligodeoxynucleotides to type I insulin-like growth factor receptor induced an antitumoral effect mediated by a CD8+ response involving Fas/Fas ligand cytotoxic pathway, J Immunol, 176, 3426, 10.4049/jimmunol.176.6.3426 Morin-Brureau, 2015, Enhancement of glioma-specific immunity in mice by “NOBEL”, an insulin-like growth factor 1 receptor antisense oligodeoxynucleotide, Cancer Immunol Immunother, 64, 447, 10.1007/s00262-015-1654-z Durfort, 2012, Small interfering RNA targeted to IGF-IR delays tumor growth and induces proinflammatory cytokines in a mouse breast cancer model, PLoS One, 7, e29213, 10.1371/journal.pone.0029213 Andrews, 2001, Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas, J Clin Oncol, 19, 2189, 10.1200/JCO.2001.19.8.2189 Andrews, 2021, Phase Ib clinical trial of IGV-001 for patients with newly diagnosed glioblastoma, Clin Cancer Res, 27, 1912, 10.1158/1078-0432.CCR-20-3805 Harshyne, 2015, Glioblastoma exosomes and IGF-1R/AS-ODN are immunogenic stimuli in a translational research immunotherapy paradigm, Cancer Immunol Immunother, 64, 299, 10.1007/s00262-014-1622-z Yuen, 2009, Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer, Mol Cancer Therapeut, 8, 1448, 10.1158/1535-7163.MCT-09-0101 Khodaei, 2021, DDAB cationic lipid-mPEG, PCL copolymer hybrid nano-carrier synthesis and application for delivery of siRNA targeting IGF-1R into breast cancer cells, Clin Transl Oncol, 23, 1167, 10.1007/s12094-020-02507-3 Gualberto, 2009, Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions, Oncogene, 28, 3009, 10.1038/onc.2009.172 Olmos, 2010, Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside, Cancer J, 16, 183, 10.1097/PPO.0b013e3181dbebf9 Wang, 2014, Anti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3, J Ovarian Res, 7, 103, 10.1186/s13048-014-0103-5 Broussas, 2009, Molecular mechanisms involved in activity of h7C10, a humanized monoclonal antibody, to IGF-1 receptor, Int J Cancer, 124, 2281, 10.1002/ijc.24186 Calzone, 2013, Epitope-specific mechanisms of IGF1R inhibition by ganitumab, PLoS One, 8, e55135, 10.1371/journal.pone.0055135 Fuchs, 2015, A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial, Ann Oncol, 26, 921, 10.1093/annonc/mdv027 Langer, 2014, Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer, J Clin Oncol, 32, 2059, 10.1200/JCO.2013.54.4932 Sclafani, 2015, A randomized phase II/III study of dalotuzumab in combination with cetuximab and irinotecan in chemorefractory, KRAS wild-type, metastatic colorectal cancer, J Natl Cancer Inst, 107, djv258, 10.1093/jnci/djv258 Zheng, 2012, Β-Arrestin-biased agonism as the central mechanism of action for insulin-like growth factor 1 receptor-targeting antibodies in Ewing's sarcoma, Proc Natl Acad Sci USA, 109, 20620, 10.1073/pnas.1216348110 Cohen, 2005, Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751, 871, Clin Cancer Res, 11, 2063, 10.1158/1078-0432.CCR-04-1070 Chughtai, 2020, The nuclear translocation of insulin-like growth factor receptor and its significance in cancer cell survival, Cell Biochem Funct, 38, 347, 10.1002/cbf.3479 Frappaz, 2016, Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours, Eur J Cancer, 62, 9, 10.1016/j.ejca.2016.03.084 Huang, 2011, R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing’s sarcoma: convergence at the IGF/IGFR/Akt axis, PLoS One, 6, e26060, 10.1371/journal.pone.0026060 Vlahovic, 2018, A phase I trial of the IGF-1R antibody ganitumab (AMG 479) in combination with everolimus (RAD001) and panitumumab in patients with advanced cancer, Oncol, 23, 782, 10.1634/theoncologist.2016-0377 Tap, 2012, Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors, J Clin Oncol, 30, 1849, 10.1200/JCO.2011.37.2359 Tolcher, 2009, Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1, J Clin Oncol, 27, 5800, 10.1200/JCO.2009.23.6745 Kindler, 2012, A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer, Ann Oncol, 23, 2834, 10.1093/annonc/mds142 McCaffery, 2013, Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor, Clin Cancer Res, 19, 4282, 10.1158/1078-0432.CCR-12-1840 Cen, 2007, Phosphorylation profiles of protein kinases in alveolar and embryonal rhabdomyosarcoma, Mod Pathol, 20, 936, 10.1038/modpathol.3800834 Abraham, 2012, An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma, Biochem Biophys Res Commun, 426, 363, 10.1016/j.bbrc.2012.08.092 Kundranda, 2020, Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE), Ann Oncol, 31, 79, 10.1016/j.annonc.2019.09.004 Camblin, 2018, Dual inhibition of IGF-1R and ErbB3 enhances the activity of gemcitabine and nab-paclitaxel in preclinical models of pancreatic cancer, Clin Cancer Res, 24, 2873, 10.1158/1078-0432.CCR-17-2262 Camblin, 2019, Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer, Sci Rep, 9, 16832, 10.1038/s41598-019-53322-y de Bono, 2020, Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours, Br J Cancer, 122, 1324, 10.1038/s41416-020-0774-1 Friedbichler, 2014, Pharmacodynamic and antineoplastic activity of BI 836845, a fully human IGF ligand-neutralizing antibody, and mechanistic rationale for combination with rapamycin, Mol Cancer Therapeut, 13, 399, 10.1158/1535-7163.MCT-13-0598 Cao, 2020, Blockade of IGF/IGF-1R signaling axis with soluble IGF-1R mutants suppresses the cell proliferation and tumor growth of human osteosarcoma, Am J Cancer Res, 10, 3248 Zhang, 2021, IGF-1R anti-idiotypic antibody antagonist exhibited anti-ovarian cancer bioactivity and reduced cisplatin resistance, Hum Cell, 34, 1197, 10.1007/s13577-021-00535-x King, 2014, Can we unlock the potential of IGF-1R inhibition in cancer therapy?, Cancer Treat Rev, 40, 1096, 10.1016/j.ctrv.2014.07.004 Carboni, 2009, BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR, Mol Cancer Therapeut, 8, 3341, 10.1158/1535-7163.MCT-09-0499 Kuhn, 2012, Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma, Blood, 120, 3260, 10.1182/blood-2011-10-386789 Khan, 2021, A phase-1 trial of linsitinib (OSI-906) in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma, Leuk Lymphoma, 62, 1721, 10.1080/10428194.2021.1876864 Ekman, 2016, A novel oral insulin-like growth factor-1 receptor pathway modulator and its implications for patients with non-small cell lung carcinoma: a phase I clinical trial, Acta Oncol, 55, 140, 10.3109/0284186X.2015.1049290 Aiken, 2017, Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of dose and response, Oncotarget, 8, 81501, 10.18632/oncotarget.20662 Scopim-Ribeiro, 2021, NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia, Invest N Drugs, 39, 736, 10.1007/s10637-020-01028-8 Chalouni, 2018, Fate of antibody-drug conjugates in cancer cells, J Exp Clin Cancer Res, 37, 20, 10.1186/s13046-017-0667-1 Hafeez, 2020, Antibody-drug conjugates for cancer therapy, Molecules, 25, E4764, 10.3390/molecules25204764 Akla, 2020, Efficacy of the antibody-drug conjugate W0101 in preclinical models of IGF-1 receptor overexpressing solid tumors, Mol Cancer Therapeut, 19, 168, 10.1158/1535-7163.MCT-19-0219 Venepalli, 2019, Phase I study of IGF-methotrexate conjugate in the treatment of advanced tumors expressing IGF-1R, Am J Clin Oncol, 42, 862, 10.1097/COC.0000000000000611 McTavish, 2009, Novel insulin-like growth factor-methotrexate covalent conjugate inhibits tumor growth in vivo at lower dosage than methotrexate alone, Transl Res, 153, 275, 10.1016/j.trsl.2009.02.005 Alkhateeb, 2020, Phase 1b study of IGF-methotrexate conjugate in the treatment of high-grade myelodysplastic syndromes, Anticancer Res, 40, 3883, 10.21873/anticanres.14378 Solomon, 2020, Development and preclinical evaluation of cixutumumab drug conjugates in a model of insulin growth factor receptor I (IGF-1R) positive cancer, Sci Rep, 10, 18549, 10.1038/s41598-020-75279-z Hua, 2020, Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy, J Hematol Oncol, 13, 64, 10.1186/s13045-020-00904-3 Chitnis, 2014, IGF-1R inhibition enhances radiosensitivity and delays double-strand break repair by both non-homologous end-joining and homologous recombination, Oncogene, 33, 5262, 10.1038/onc.2013.460 Ramcharan, 2015, IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide, Oncotarget, 6, 39877, 10.18632/oncotarget.5631 Singh, 2014, IGF-1R inhibition potentiates cytotoxic effects of chemotherapeutic agents in early stages of chemoresistant ovarian cancer cells, Cancer Lett, 354, 254, 10.1016/j.canlet.2014.08.023 Aleksic, 2010, Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells, Cancer Res, 70, 6412, 10.1158/0008-5472.CAN-10-0052 Warsito, 2012, Nuclear IGF1R is a transcriptional co-activator of LEF1/TCF, EMBO Rep, 13, 244, 10.1038/embor.2011.251 Jones, 2004, Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells, Endocr Relat Cancer, 11, 793, 10.1677/erc.1.00799 Wang, 2020, Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer, Nat Commun, 11, 4607, 10.1038/s41467-020-18442-4 MacAulay, 2016, Phase I dose-escalation study of Linsitinib (OSI-906) and Erlotinib in patients with advanced solid tumors, Clin Cancer Res, 22, 2897, 10.1158/1078-0432.CCR-15-2218 Leighl, 2017, Phase 2 study of Erlotinib in combination with Linsitinib (OSI-906) or placebo in chemotherapy-naive patients with non-small-cell lung cancer and activating epidermal growth factor receptor mutations, Clin Lung Cancer, 18, 34, 10.1016/j.cllc.2016.07.007 Luo, 2021, Disruption of FOXO3a-miRNA feedback inhibition of IGF2/IGF-1R/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer, Nat Commun, 12, 2699, 10.1038/s41467-021-23052-9 Browne, 2012, Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours, Breast Cancer Res Treat, 136, 717, 10.1007/s10549-012-2260-9 Zhang, 2018, IGF1R signaling drives antiestrogen resistance through PAK2/PIX activation in luminal breast cancer, Oncogene, 37, 1869, 10.1038/s41388-017-0027-9 Ye, 2003, Combined effects of tamoxifen and a chimeric humanized single chain antibody against the type I IGF receptor on breast tumor growth in vivo, Horm Metab Res, 35, 836 Chakraborty, 2010, Co-targeting the insulin-like growth factor I receptor enhances growth-inhibitory and pro-apoptotic effects of anti-estrogens in human breast cancer cell lines, Breast Cancer Res Treat, 120, 327, 10.1007/s10549-009-0382-5 McDermott, 2017, Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells, Int J Oncol, 50, 2221, 10.3892/ijo.2017.3976 Flanigan, 2013, Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models, Clin Cancer Res, 19, 6219, 10.1158/1078-0432.CCR-13-0145 Cao, 2015, Combinational therapy enhances the effects of anti-IGF-1R mAb figitumumab to target small cell lung cancer, PLoS One, 10, e0135844, 10.1371/journal.pone.0135844 Xue, 2021, Metformin and an insulin/IGF-1 receptor inhibitor are synergistic in blocking growth of triple-negative breast cancer, Breast Cancer Res Treat, 185, 73, 10.1007/s10549-020-05927-5 Fuentes-Baile, 2020, Differential effects of IGF-1R small molecule tyrosine kinase inhibitors BMS-754807 and OSI-906 on human cancer cell lines, Cancers, 12, E3717, 10.3390/cancers12123717 Lee, 2015, STAT3-mediated IGF-2 secretion in the tumour microenvironment elicits innate resistance to anti-IGF-1R antibody, Nat Commun, 6, 8499, 10.1038/ncomms9499 Bano, 2020, Analyzing structural differences between insulin receptor (IR) and IGF1R for designing small molecule allosteric inhibitors of IGF1R as novel anti-cancer agents, Growth Hormone IGF Res, 55, 101343, 10.1016/j.ghir.2020.101343 Codony-Servat, 2017, Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer, Br J Cancer, 117, 1777, 10.1038/bjc.2017.279 Aleksic, 2018, Nuclear IGF1R interacts with regulatory regions of chromatin to promote RNA polymerase II recruitment and gene expression associated with advanced tumor stage, Cancer Res, 78, 3497, 10.1158/0008-5472.CAN-17-3498 Sehat, 2010, SUMOylation mediates the nuclear translocation and signaling of the IGF-1 receptor, Sci Signal, 3, ra10, 10.1126/scisignal.2000628 Deng, 2011, Over-accumulation of nuclear IGF-1 receptor in tumor cells requires elevated expression of the receptor and the SUMO-conjugating enzyme Ubc9, Biochem Biophys Res Commun, 404, 667, 10.1016/j.bbrc.2010.12.038